Krsnaa Diagnostics Ltd (KRSNAA) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company emphasized its strategic positioning as a national healthcare infrastructure platform for "Bharat," leveraging a Public-Private Partnership (PPP) model to provide affordable and accessible diagnostics, differentiating itself from traditional asset-light, urban-focused players.
- The quarter was marked by disciplined execution, with a focus on strengthening the balance sheet, evidenced by the highest-ever quarterly collection of 1580 million and a reduction in receivable days from 155 to 139.
- Significant progress was made on major expansion projects, particularly the substantial implementation of the Rajasthan PPP project and the commencement of new MRI center installations, which are set to drive future growth.
- The retail diagnostics business has emerged as a key strategic growth engine, contributing approximately 8% to the full-year revenue and showing strong underlying momentum with an expanding network of over 3500 touchpoints.
- The company reported a robust financial performance for the quarter, with a 4% YoY revenue growth and a strong EBITDA margin of 29%, reflecting operational efficiency despite ongoing large-scale capital investments.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.